Value Contribution of Palopegteriparatide in Adult Patients with Chronic Hypoparathyroidism using Multicriteria Decision Analysis (MCDA)
According to MCDA, palopegteriparatide represents a valuable therapeutic option for chronic hypoparathyroidism treatment, particularly due to its demonstrated efficacy, which had an impact on patients' QoL, and the current unmet needs in this therapeutic area.
Authors
- Xavier Badía (ORCID: https://orcid.org/0000-0001-7568-2550)
- Josep Maria Guiu
- Manuel Muñoz‐Torres (ORCID: https://orcid.org/0000-0002-9645-3260)
- Mónica Climente Martí (ORCID: https://orcid.org/0000-0002-4387-1987)
- Carmen Alerany
- Juan J. Díez (ORCID: https://orcid.org/0000-0002-2017-0694)
- Isabel Hierro Martín
- María Caballero
- R Abad
Institutions
- Universidade da Coruña (ES)
- Hebron University (PS)
- Universitat de València (ES)
- Universidad de Granada (ES)
- Instituto de Salud Carlos III (ES)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Oblikue Consulting (Spain) (ES)
- Instituto de Investigación Biosanitaria de Granada (ES)
- Hospital Universitario Miguel Servet (ES)
- Hospital Universitario Doctor Peset (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (ES)
- Consortium for Health and Social Catalonia (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1007/s12325-025-03396-0
- Citations
- 1
- Primary Topic
- Thyroid and Parathyroid Surgery
- Type
- article
- Field-Weighted Citation Impact
- 2.01